I am a medicinal and synthetic organic chemist with over 10+ years of experience in drug discovery, including 7+ years in CRO/industrial research at Jubilant Chemsys Ltd. and 4+ years in academic drug discovery. My expertise spans multi-step organic synthesis, medicinal chemistry, SAR optimization, heterocyclic chemistry, hit-to-lead development, and process scale-up, supporting discovery programs for global pharmaceutical partners including Janssen, Merck, GSK, Abbott, and IDRI.
I am currently a Postdoctoral Researcher at Wayne State University, where my research focuses on the design and synthesis of novel small molecules, including the development of non-cytotoxic phosphazene superbases for high-throughput synthesis and direct-to-biology (D2B) applications.
I received my Ph.D. in Pharmaceutical Chemistry from the University of KwaZulu-Natal, South Africa. Throughout my career, I have contributed to the design, synthesis, and optimization of multiple bioactive molecules across oncology, infectious disease, and drug discovery programs. Notably, I designed and synthesized NERx-3392, a promising small molecule demonstrating strong in vivo efficacy and advancing through the drug development pipeline.
I am a medicinal and synthetic organic chemist with over 10+ years of experience in drug discovery, including 7+ years in CRO/industrial research at Jubilant Chemsys Ltd. and 4+ years in academic drug discovery. My expertise spans multi-step organic synthesis, medicinal chemistry, SAR optimization, heterocyclic chemistry, hit-to-lead development, and process scale-up, supporting discovery programs for global pharmaceutical partners including Janssen, Merck, GSK, Abbott, and IDRI.
I am currently a Postdoctoral Researcher at Wayne State University, where my research focuses on the design and synthesis of novel small molecules, including the development of non-cytotoxic phosphazene superbases for high-throughput synthesis and direct-to-biology (D2B) applications.
I received my Ph.D. in Pharmaceutical Chemistry from the University of KwaZulu-Natal, South Africa. Throughout my career, I have contributed to the design, synthesis, and optimization of multiple bioactive molecules across oncology, infectious disease, and drug discovery programs. Notably, I designed and synthesized NERx-3392, a promising small molecule demonstrating strong in vivo efficacy and advancing through the drug development pipeline.